Viridian Therapeutics, Inc. (VRDN) Financials

$19.76

north_east
$0.59 (3.08%)
Day's range
$19.14
Day's range
$19.81

VRDN Income statement / Annual

Last year (2023), Viridian Therapeutics, Inc.'s total revenue was $314,000.00, a decrease of 82.28% from the previous year. In 2023, Viridian Therapeutics, Inc.'s net income was -$237.73 M. See Viridian Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $314,000.00 $1.77 M $2.96 M $1.05 M $4.46 M $8.39 M $4.00 M $3.34 M $2.54 M $4.32 M
Cost of Revenue $1.32 M $755,000.00 $620,000.00 $28.30 M $32.79 M $30.42 M $19.62 M $2.55 M $2.47 M $3.24 M
Gross Profit -$1.01 M $1.02 M $2.34 M -$27.25 M -$28.33 M -$22.04 M -$15.62 M $789,000.00 $66,000.00 $1.08 M
Gross Profit Ratio -3.21 0.57 0.79 -25.96 -6.35 -2.63 -3.9 0.24 0.03 0.25
Research and Development Expenses $159.77 M $100.89 M $56.89 M $28.30 M $34.79 M $30.42 M $19.62 M $888,000.00 $1.00 M $293,000.00
General & Administrative Expenses $95.00 M $35.18 M $25.81 M $13.27 M $11.65 M $11.05 M $10.91 M $7.91 M $7.69 M $7.03 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $1.67 M $2.56 M $717,000.00
Selling, General & Administrative Expenses $95.00 M $35.18 M $25.81 M $13.27 M $11.65 M $11.05 M $10.91 M $9.58 M $10.25 M $7.75 M
Other Expenses $0.00 $0.00 $0.00 $69.86 M $0.00 $0.00 $0.00 $2.83 M $0.00 $0.00
Operating Expenses $254.76 M $136.08 M $82.69 M $41.57 M $46.44 M $41.47 M $30.54 M $10.46 M $11.25 M $8.04 M
Cost And Expenses $254.76 M $136.08 M $82.69 M $41.57 M $46.44 M $41.47 M $30.54 M $13.01 M $13.73 M $11.29 M
Interest Income $18.56 M $4.92 M $318,000.00 $173,000.00 $941,000.00 $1.25 M $403,000.00 $0.00 $0.00 $0.00
Interest Expense $1.85 M $486,000.00 $3,000.00 $508,000.00 $835,000.00 $873,000.00 $383,000.00 $95,000.00 $141,000.00 $1.02 M
Depreciation & Amortization $522,000.00 $755,000.00 $620,000.00 $539,000.00 $288,000.00 $281,000.00 $308,000.00 $341,000.00 $184,000.00 $144,000.00
EBITDA -$234.57 M -$128.63 M -$78.79 M -$109.67 M -$40.75 M -$31.55 M -$25.82 M -$12.51 M -$11.00 M -$6.72 M
EBITDA Ratio -747.02 -73.02 -26.76 -38.42 -9.2 -3.8 -6.53 -2.84 -4.34 -1.58
Operating Income Ratio -810.35 -75.79 -26.91 -105.12 -9.41 -3.95 -6.63 -3.75 -4.41 -1.59
Total Other Income/Expenses Net $16.72 M $4.43 M $315,000.00 -$335,000.00 $106,000.00 $381,000.00 $20,000.00 -$166,000.00 -$141,000.00 -$1.02 M
Income Before Tax -$237.73 M -$129.87 M -$79.41 M -$110.72 M -$41.87 M -$32.70 M -$26.51 M -$12.67 M -$11.33 M -$7.89 M
Income Before Tax Ratio -757.11 -73.29 -26.8 -105.44 -9.39 -3.9 -6.62 -3.8 -4.46 -1.83
Income Tax Expense $0.00 -$4.43 M $3,000.00 $269,000.00 $547,000.00 $1.25 M $95,000.00 $95,000.00 $0.00 $1.02 M
Net Income -$237.73 M -$125.44 M -$79.42 M -$110.98 M -$42.42 M -$32.70 M -$26.51 M -$12.67 M -$11.33 M -$7.89 M
Net Income Ratio -757.11 -70.79 -26.8 -105.7 -9.51 -3.9 -6.62 -3.8 -4.46 -1.83
EPS -5.31 -3.91 -6.66 -31.2 -20.31 -16.57 -20.66 -17.57 -21 -52.46
EPS Diluted -5.31 -3.91 -6.66 -31.2 -20.31 -16.57 -20.66 -17.57 -21 -52.46
Weighted Average Shares Out $44.76 M $32.09 M $11.92 M $3.56 M $2.09 M $1.97 M $1.28 M $721,410.00 $539,445.00 $150,390.00
Weighted Average Shares Out Diluted $44.76 M $32.09 M $11.92 M $3.56 M $2.09 M $1.97 M $1.28 M $721,410.00 $539,460.00 $150,390.00
Link